Open AccessEvaluation of Pathologic Response on Overall Survival After Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma
Author(s) -
Naomi M. Sell,
Grace C. Lee,
Carlos Fernández-Del Castillo,
Cristina R. Ferrone,
Andrew L. Warshaw,
Theodore S. Hong,
Lawrence S. Blaszkowsky,
Keith D. Lillemoe,
Motaz Qadan
Publication year - 2020
Publication title -
pancreas
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.061
H-Index - 104
eISSN - 1536-4828
pISSN - 0885-3177
DOI - 10.1097/mpa.0000000000001590
Subject(s) - medicine , neoadjuvant therapy , pancreatectomy , pancreatic cancer , lymph node , oncology , adenocarcinoma , chemotherapy , proportional hazards model , primary tumor , pancreas , radiation therapy , pancreatic ductal adenocarcinoma , cancer , gastroenterology , surgery , metastasis , breast cancer
Single-institution studies have shown improved outcomes among patients with a pathologic complete response (pCR) following neoadjuvant therapy. We sought to evaluate the impact of pCR and near-complete response (nCR) on overall survival (OS) using a large national database.